Announcements Trials

Browse Landscape

Phase

Phase 1/2 2 Phase EARLY_PHASE1 1 Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 2767 Carcinoma, Non-Small-Cell Lung 2265 Prostatic Neoplasms 1427 Colorectal Neoplasms 1295 Neoplasms 1260 Multiple Myeloma 1086 Lung Neoplasms 1049 Neoplasm Metastasis 995 Leukemia, Myeloid, Acute 985 Lymphoma 900 Melanoma 864 Pancreatic Neoplasms 818 Ovarian Neoplasms 805 Carcinoma, Hepatocellular 782 Stomach Neoplasms 753 Recurrence 753 Leukemia 733 Lymphoma, Non-Hodgkin 684 Leukemia, Lymphocytic, Chronic, B-Cell 665 Squamous Cell Carcinoma of Head and Neck 618 Lymphoma, Large B-Cell, Diffuse 617 Precursor Cell Lymphoblastic Leukemia-Lymphoma 605 Head and Neck Neoplasms 598 Brain Neoplasms 593 Carcinoma, Renal Cell 587 Glioblastoma 573 Rectal Neoplasms 565 Sarcoma 523 Myelodysplastic Syndromes 522 Lymphoma, Follicular 516

Interventions

lenvatinib 1 camrelizumab 1 130-nm albumin-bound paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Advanced Triple Negative Breast Cancer × Clear all

NCT06849492 2025-02-27

SHIFT-001

Fudan University

Phase 2 Not yet recruiting

Advanced Triple Negative Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡